EHA 2014 | Myeloma Treatment and Research News

  • Promise for patients with newly diagnosed myeloma


    Dr. Ola Landgren, from Memorial Sloan Kettering, summarizes recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients.

  • The value of MRD testing in multiple myeloma


    Dr. Ola Landgren, from Memorial Sloan Kettering, describes the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma as a potential new end-point in clinical trials, and as a marker of therapeutic response.

  • Plethora of new agents in multiple myeloma


    Dr. Ola Landgren, from Memorial Sloan Kettering, summarizes the promise with the plethora of new agents in multiple myeloma. He mentions the PANORAMA study, spindle kinase inhibitors and monoclonal antibodies, such as the CD38 class. Dr Landgren comments on the two CD38-specific monoclonal antibodies, daratumumab and SAR650984, and the hope they are bringing for myeloma patients in both monotherapy and in combination.

  • Changing definition of myeloma


    Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to Patient Power from the 19th Congress of the European Haematology Association (EHA) meeting about the changed definition of multiple myeloma. A result of a 2-day workshop of the international myeloma working group before the EHA meeting, the definition now includes three additional criteria which are explained. Dr Landgren explores the reason for the altered definition and implications for clinical practice.

  • Describing today’s myeloma care and how patients can access it


    Dr Keith Stewart from Mayo Clinic highlights the newest research and recommendations for patients with myeloma, as well as making sure patients and their families have access to the most effective therapies.

  • Living Longer and Living Better with Myeloma


    Dr. Paul Richardson, an expert from the Dana-Farber Cancer Institute, provides an overview of treatments currently in trials and their potential impact on survival and quality of life.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on January 7, 2015